We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

PERKIN ELMER CORPORATION

PerkinElmer provides detection technologies to detect and identify diseases, imaging technologies to help visualize s... read more Featured Products: More products

Download Mobile App




Biomarker Evaluated for Early Detection of Congenital Heart Disease

By LabMedica International staff writers
Posted on 16 Dec 2020
Print article
Image: The GSP instrument is a high throughput batch analyzer intended for quantitative or qualitative measurement of neonatal screening samples on 96-well microplates (Photo courtesy of PerkinElmer).
Image: The GSP instrument is a high throughput batch analyzer intended for quantitative or qualitative measurement of neonatal screening samples on 96-well microplates (Photo courtesy of PerkinElmer).
Congenital heart disease (CHD) is the most common congenital malformation in humans worldwide. Circulating cardiovascular biomarkers could potentially improve the early detection of CHD, even in asymptomatic newborns.

The amino terminal fragment of the prohormone brain-type natriuretic peptide (NT-proBNP) test has been used in adults with cardiac failure. Evidence has found that the NT-proBNP test is useful in infants who require neonatal intensive care, children with pulmonary hypertension and cardiomyopathies, and children with various types of CHD.

Pediatricians at the University Teaching Hospital Ryhov (Jönköping, Sweden) and their colleagues prospectively enrolled healthy, term neonates born between July 1, 2018, and May 31, 2019 and compared them against retrospectively identified newborns with CHD born between September 1, 2003, and September 30, 2019. The CHD diagnosis was confirmed by echocardiography. Control newborns were followed-up for a minimum of one year using electronic patient records covering routine checkups and additional medical consultations.

The scientists developed a fully automated immunoassay for NT-proBNP measurement from dried blood spot (DBS) samples. Microtitration strips 96-well format were coated with anti-NT-proBNP mouse monoclonal IgG antibody (HyTest Ltd, Turku, Finland) and the monoclonal tracer antibody (HyTest Ltd) was labeled with europium chelate. The hematocrit in this mix was checked with a Coulter Ac · T diff Hematology Analyzer (Beckman Coulter, Brea, CA, USA). A high throughput batch analyzer (GSP Instrument; PerkinElmer, Waltham, MA, USA) was used for the plate assays.

Performed as early as two days after birth, a dried blood spot (DBS) test for NT-proBNP flagged 71% of the 34 tested babies with known CHD and 68% of the critical CHD cases. Combining the DBS test with pulse oximetry screening improved CHD detection to 82% and detection of critical CHD to 89%. Babies with CHD had a median NT-proBNP level of 17,240 ng/L based on the DBS test. Healthy controls had significantly lower NT-proBNP levels, with a median of 1,900 ng/L. A comparison of DBS and standard screening for NT-proBNP (laboratory analysis on 500 μL of blood in a collection tube containing EDTA as an anticoagulant) found the two tests to be highly correlated and in good agreement.

The authors concluded that the DBS NT-proBNP test discriminated well between healthy newborns and newborns with various types of CHD, including critical lesions. Additional reference values were established for days two to four of life, reflecting the timing of common newborn screening programs. The study was published on December 2, 2020 in the journal JAMA Network Open.

Related Links:
University Teaching Hospital Ryhov
HyTest Ltd
Beckman Coulter
PerkinElmer


Gold Member
Pharmacogenetics Panel
VeriDose Core Panel v2.0
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Immunoassays and Calibrators
QMS Tacrolimus Immunoassays
New
Silver Member
HPV Molecular Controls
ZeptoMetrix® HPV Type 16, 18, 45 & 68 Molecular Controls

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The ready-to-use DUB enzyme assay kits accelerate routine DUB activity assays without compromising data quality (Photo courtesy of Adobe Stock)

Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation

Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.